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Faculty of Medicine, Tel-Aviv University, Tel-Aviv, IsraelA B S T R A C TBackground: The effectiveness of value-based insurance design is
based on nonadherence, which derives solely from patients’ economic
constraints. Objective: Our objective was to examine the extent of
cost-related nonadherence to chronic medications and to analyze its
potential determinants. Methods: We conducted a telephone survey
among a representative sample of Maccabi Healthcare Services chroni-
cally ill patients aged 55 years or older (n ¼ 522). We developed a 12-
month recall questionnaire that included demographic and socio-
economic characteristics, out-of-pocket expenditure on prescribed
medication, physician’s provision of explanation regarding prescribed
therapy, adherence, and reasons for nonadherence. Respondents were
deﬁned as nonadherent if they reported that they did not purchase
prescribed medications in the previous year because of their cost. We
applied the multivariable logistic regression model to examine pre-
dictors of nonadherence. Results: Median (interquartile range) age of
the study sample was 69 (13) years (53%males). One hundred sixty-ﬁve
patients (31.6%) reported not purchasing prescribed medications
mainly because of medications’ adverse effects and/or cost. Fifty res-ee front matter Copyright & 2014, International S
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nt, Ben-Gurion University of the Negev, P.O.B. 653pondents (9.6%) reported cost-related nonadherence. The multivari-
able logistic regression model revealed that cost-related nonadherence
was associated with respondent’s income lower than 4600 New Israeli
shekel (odds ratio [OR] ¼ 10.86; 95% conﬁdence interval [CI] 1.45–81.12),
unemployment (OR ¼ 4.32; 95% CI 1.47–12.66), lack of physician
explanation about the prescribed medication (OR ¼ 2.38; 95% CI 1.18–
4.78), and age (OR ¼ 0.95; 95% CI 0.91–0.99). Conclusions: Cost-related
nonadherence to chronic pharmaceuticals is self-reported among
nearly 10% of the chronically ill patients and is strongly affected by
low socioeconomic status, even under universal health insurance
coverage and with relatively low co-payments as applied in Israel.
Lack of information provided by physicians regarding the therapy is
associated with a higher likelihood of cost-related nonadherence.
Keywords: chronic medications, co-payment, cost, nonadherence,
value-based insurance design.
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Co-payments for pharmaceuticals and other health care services
are usually used by health insurers as a measure of reducing
health care costs. Co-payment policies may achieve two main
goals: ﬁrst, curbing excessive utilization of unnecessary health
services, and second, shifting the burden of health care ﬁnancing
from public to private sources. Although patient co-payments
may prevent excessive health expenditures, they may be a barrier
to essential care, thus resulting in adverse health outcomes and
increased health care expenditures [1–3].
Following the enactment of the National Health Insurance
Law in Israel (1995), all citizens have universal health insurance
coverage providing access to a broad beneﬁts package including
physician consultations, ambulatory care, hospitalization, andmedications. Citizens are free to enroll in one of four competing
nonproﬁt health plans (health maintenance organizations) that
are obligated to provide them equal access to all the services
speciﬁed by the National Health Insurance Law. As of 1998, in an
attempt to increase their revenues, health plans were allowed to
increase co-payment charges [4]. The co-payments for chronic
medications in the second largest health plan in Israel, Maccabi
Healthcare Services (MHS), is 10% to 15% or 15 New Israeli shekel
(NIS) per prescription (US $4.3). In the absence of exemptions,
co-payments place a substantial ﬁnancial burden on the poor, the
elderly, and the chronically ill. To minimize access barriers to the
care of these vulnerable populations, a quarterly ceiling for
pharmaceuticals’ co-payments was set for chronically ill patients,
those receiving welfare payments, and holocaust survivors.
Results from a recent survey in Israel conducted by the Myers-ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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cally ill patients reported not buying a prescribed medication
because of its cost [5].
Value-based insurance design (VBID) is a measure to contain
costs while improving quality of care, through linking patient’s
co-payments to service value in terms of beneﬁt to patient’s
health, rather than to its cost. It is expected that reducing co-
payments to those who will beneﬁt most will increase patient
adherence, improve health outcomes, and may reduce overall
costs to the patient and the health insurer [6–8]. These designs
are commonly applied by employers and health insurers in the
United States on prescription drug therapy for chronically ill
patients [9]. They were found to be cost-effective in post–myo-
cardial infarction and angiotensin-converting enzyme inhibitor
therapy for diabetic patients [10,11], and were associated with
favorable health beneﬁts [12] without increasing overall health
care spending [9,12–15]. These favorable implications of VBIDs
stem predominantly from the improvement in patients’ adher-
ence to prescribed medications [2,13,14,16–23]. Poor adherence to
chronic medication therapy has been long recognized as a major
driver of adverse health outcomes. Recent examples reinforced
this argument, by demonstrating positive association between
adherence to medication and health outcomes among chronic
conditions such as cardiovascular disease, hypertension, and
diabetes [24–26].
Patient-related reasons for nonadherence include among
others forgetfulness, competing priorities, decision to omit doses,
lack of adequate awareness of the clinical importance of the
medication, and emotional factors. A considerable portion of
respondents, however, does not provide reasons for their under-
use [27]. Cost-related nonadherence is a well-explored phenom-
enon in developed countries and is prevalent in 13% to 28% of the
respondents in the United States [25,28–40], 12% in Switzerland
[41], 4% to 12% in different provinces in Canada [39,40], and 3% to
13% in United Kingdom, The Netherlands, Germany, Australia,
and New Zealand [39]. Reduction in cost-related nonadherence
was associated with improved health outcome [25,42,43]. People
with more generous health insurance coverage may be less
vulnerable to cost-related underuse [39,40,44]. The extent to
which VBID may be an effective and feasible policy in Israel
relies primarily on the proportion of chronically ill patients who
do not reﬁll their prescription solely for ﬁnancial reasons. In
addition, a negative association between nonadherence, adverse
health outcomes, and overall health care spending needs to be
conﬁrmed.
To provide preliminary information on the expected effective-
ness of VBID in our health care system, the present study aimed
to examine to what extent nonadherence of chronically ill
patients to medication regimens is related to ﬁnancial reasons.
We analyzed the determinants associated with cost-related non-
adherence in the context of the Israeli health system, which
provides more generously universal health insurance coverage,
as compared with the United States. We hypothesized that
nonadherence stems to some extent solely from ﬁnancial rea-
sons even in the Israeli health care system and that socio-
economic status is an independent determinant of cost-related
nonadherence.Methods
A telephone survey was conducted during 2012 among enrollees
of MHS, the second largest health plan in Israel, providing health
care for approximately 2 million members. The study was
approved by the Institutional Ethics Committee. The study
population was a representative sample of MHS enrollees aged
55 years or older, who are included in the Diabetes andCardiovascular Disease Registry of the MHS. The algorithm used
to enroll patients in this registry is based, among other criteria,
on evidence of prescription reﬁll of chronic medications. This
sample was chosen using computer-generated random selection.
We developed a 12-month recall questionnaire that was
partially based on a validated questionnaire developed by the
Myers-JDC-Brookdale Institute [5]. The questionnaire included
demographic and socioeconomic characteristics such as age,
sex, marital status, education, and income; self-reported out-of-
pocket expenditure on prescribed medication; question on
whether physician provided them explanation regarding pre-
scribed medications; self-reported adherence; and reasons for
nonadherence.
Respondents were deﬁned as nonadherent because of ﬁnan-
cial reasons if they reported not purchasing at least one of their
prescribed medications over a period of 12 months before the
interview date because of their cost (i.e., patients’ co-payment).
Respondent who reported not purchasing prescribed medications
because of different reasons, such as adverse effects, difﬁculties
in adapting to dosage regimens, forgetfulness, interest in alter-
native treatment, or having a feeling that they are healed, were
not deﬁned as nonadherent because of ﬁnancial reasons.
All continuous variables were non-normally distributed and
presented as mean  SD and median (interquartile range).
Dichotomous indicator values are presented as proportions.
Comparison between group medians and proportions was done
using Mann-Whitney U test and chi-square test, respectively. We
used multivariable logistic regression analysis to examine pre-
dictors of nonadherence (dependent variable). Independent var-
iables included age, sex, marital status, being a new immigrant to
Israel, possession of supplemental insurance, employment sta-
tus, education, income, out-of-pocket expenditure on prescribed
medication, and receiving physician explanation regarding pre-
scribed medications. Data were analyzed using STATA software
(version 11.0, StataCorp, College Station, TX.) P values of o0.05
determined statistical signiﬁcance in all analyses.Results
Five hundred twenty-two chronically ill patients were included in
our analysis (median age of 69 years (13) and 53% males). One
hundred sixty-ﬁve patients (31.6%) reported not purchasing
prescribed medications mainly because of their adverse effects
and/or cost. Fifty patients (9.6% of the study sample) reported
cost-related nonadherence. Of these, 36 (72%) stated that they did
not adhere to at least one of their prescribed chronic medication
solely because of its cost and 14 (28%) reported cost-related
underuse in addition to other reason (mainly adverse effects).
Forty-three patients (86% of the nonadherent patients) stated
that they would have bought the medication if its cost was lower
(one patient reported that he would not purchase even if its cost
was lower, and six patients reported that they were not sure).
As depicted in Table 1, adherent patients (n ¼ 464) were
comparable to nonadherent patients in their demographic and
socioeconomic characteristics (e.g., age, sex, education, and
possession of voluntary supplementary health insurance), with
only two exceptions. First, a signiﬁcantly lower proportion of
nonadherent respondents reported that they had worked during
3 months before the interview date (10% vs. 31.9%, respectively;
P ¼ 0.001). Second, a signiﬁcantly higher proportion of non-
adherent respondents reported having a household income lower
than 4600NIS (US $1314) per month (52.0% vs. 26.5%, respectively;
P ¼ 0.002). However, no signiﬁcant differences between groups
were found with regard to the reported monthly out-of-pocket
expenditure on prescribed medications (Table 2). Finally, as
presented in Table 2, a signiﬁcantly lower proportion of
Table 1 – Comparison of characteristics between adherent and nonadherent chronically ill patients.
Characteristic Nonadherent Adherent P
n 50 464
Sex: male, % 48.0 53.0 0.50*
Age (y)† 68.7  9.3, 66 (12) 70.0  8.9, 69 (13) 0.18‡
% live alone 28.0 25.2 0.67*
Family size† 2.4  1.4, 2 (1) 2.7  1.8, 2 (1) 0.33‡
% new immigrants 12.0 12.0 0.99*
Continent of birth (%)
Israel 42.0 31.0 0.30*
Europe 36.0 33.6
Asia 10.0 19.4
North Africa 4.0 9.7
USA and Canada 8.0 6.0
% owning supplementary insurance 90.0 92.0 0.62*
% employed in the last 3 mo 10.0 31.9 0.001*
Monthly household income (NIS), %
o4,600 52.0 26.5 0.002*
4,600–8,000 18.0 17.2
8,000–12,500 8.0 16.1
Z 12,500 2.0 12.0
Not reported 20.0 28.2
Education (%)
No formal education 0.0 2.4 0.51*
Elementary and secondary 48.0 44.6
Higher education 52.0 53.0
NIS, New Israeli shekels.
* Chi-square test.
† Values are mean  SD, median (interquartile range).
‡ Mann-Whitney U test.
Table 3 – Multivariable logistic regression model* of
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explanation regarding their medication therapy (69.4% vs. 82.7%,
respectively; P ¼ 0.04).
A multivariable analysis revealed three main determinants
associated with cost-related nonadherence (Table 3). First, com-
pared with respondents who reported a monthly household incomeTable 2 – Relationship between adherence, monthly
out-of-pocket expenditure, and physician
explanation.
Variable Nonadherent Adherent P
n 50 464
% monthly out-of-
pocket
expenditure (NIS)
for prescribed
medication of
r50 8.2 13.3 0.49*
51–150 24.5 30.7
151–250 18.4 15.6
4250 49.0 40.5
% Receiving
physician
explanation
regarding
prescribed
medication
69.4 82.7 0.04*
NIS, New Israeli shekels.
* Chi-square test.of 12,500NIS (US $3500) or higher, respondents who reported a
monthly household income of lower than 4600NIS (US $1300) had
approximately 11 times higher likelihood to be nonadherentthe determinants of nonadherence.
Variable OR 95% CI P
Age (year þ 1) 0.95 0.91–0.99 0.024
Monthly household
income (NIS)
Z12,500 1 (reference)
8,000–12,500 3.24 0.36–29.01 0.293
4,600–8,000 5.45 0.68–43.67 0.110
o4,600 10.86 1.45–81.12 0.020
Worked during the last 3 mo
Yes 1 (reference)
No 4.32 1.47–12.66 0.008
Not receiving physician
explanation
regarding prescribed
medication (vs.
receiving one)
2.38 1.18–4.78 0.015
Note. Excluded from the model because of insigniﬁcant associa-
tion: sex, living alone (vs. couples), family size, being an immi-
grant, continent of birth, having supplementary insurance,
education, and monthly out-of-pocket expenditure for prescribed
medication.
CI, conﬁdence interval; NIS, New Israeli shekels; OR, odds ratio;
ROC, receiver operating characteristic.
* n ¼ 504; area under ROC curve ¼ 0.75.
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ﬁdence interval [CI] 1.45–81.12). Second, respondents who were
unemployed during 3 months before the interview date were more
likely to report cost-related nonadherence (OR ¼ 4.32; 95% CI 1.47–
12.66). And third, lack of physician explanation about prescribed
medication increased the odds of reporting cost-related underuse
(OR ¼ 2.38; 95% CI 1.18–4.78) (Table 3). In the presence of these
covariates, older age was associated with a lower likelihood of cost-
related nonadherence (OR ¼ 0.95; 95% CI 0.91–0.99).Discussion
Our ﬁndings suggest that cost-related nonadherence to chronic
pharmaceuticals is self-reported among nearly 10% of the chroni-
cally ill patients and is strongly affected by low socioeconomic
status, even under universal health insurance coverage and with
relatively low co-payments that are applied in Israel. In addition,
a notable ﬁnding of our survey is that cost-related underuse is
associated with lack of information provided by physicians
regarding the prescribed therapy. The following discussion con-
siders these results in light of the currently available literature.
Approximately 10% of our study sample reported cost-related
nonadherence in the previous year. This proportion is lower than
that found in previous studies conducted in the United States
among patients with various chronic comorbidities [29–32,34–38],
patients with diabetes [28,33,45,46], and patients with cardiovas-
cular disease [25], where 13% to 28% of the respondents reported
cost-related nonadherence. This difference may be attributed to
two main reasons. The ﬁrst is differences in health insurance
coverage. Chronically ill patients in Israel have universal health
insurance coverage that is provided by the National Health
Insurance Law with a broad beneﬁts package that is mostly
publicly subsidized, whereas chronically ill patients in the United
States hold relatively less generous and/or privately ﬁnanced
health insurance coverage. The relatively more progressive
ﬁnance design in Israel may present lower barriers to care
compared with the United States [47,48], thus resulting in lower
rates of cost-related nonadherence. This argument is reinforced
by the fact that similar rates of cost-related underuse were
reported by respondents from countries with mandatory and
mostly publicly ﬁnanced health insurance coverage such as
Ontario, British Columbia, and Manitoba in Canada [39], Switzer-
land [41], and Germany [40], yet the rate of cost-related non-
adherence in our study was somewhat higher than the rate
reported in the United Kingdom and The Netherlands [40]. The
second reason for the relatively low rates of nonadherence may
stem from the fact that our respondents were relatively old.
Compared with 13% to 15% of the respondents mostly older than
65 years who reported cost-related underuse in several studies
[30–32,36], more than 22% of younger cohorts reported underuse
derived from ﬁnancial reasons [28,29]. Similarly, adults younger
than 65 years were more likely to report cost-related nonadher-
ence than were patients older than 65 years [33,34]. This trend
was found in other studies as well [39,40,44] and is reinforced in
our study, in which cost-related underuse was associated with
lower age in the presence of other covariates.
Nonadherence was also signiﬁcantly associated with low
socioeconomic status as measured by household income and
employment status. In particular, a higher likelihood of underuse
that stems from ﬁnancial reasons was observed among the two
lowest deciles of household income than among the highest
deciles. Similar results were found in previous studies
[29,33,36,40,41,44]. Low-income patients may be more sensitive
to higher co-payments. The pioneer study of the RAND Health
Insurance Experiment provided robust evidence for the fact that
low-income patients are more sensitive to higher co-payments[49]. Contemporary evidence reveals that patients in low-income
areas in the United States were more sensitive to changes in co-
payments than in those in high- or middle-income areas [50] and
that the negative inﬂuence of co-payment on adherence is more
likely to be present among middle-income and lower-middle-
income patients [51]. Similar ﬁndings were found in studies
conducted in Israel [52–55]. In addition, the association between
low socioeconomic status and nonadherence can be attributed to
the fact that patients from low socioeconomic status have a
greater likelihood of exposure to health risk behaviors, such as
smoking, poor diet, nonattendance to health checkups as well as
poor compliance with prescribed therapy [56,57].
An additional independent determinant of cost-related non-
adherence in our study was lack of information provided by
physicians regarding the prescribed medication. Little is known
about the role of the patient-clinician relationship in cost-related
nonadherence [44]. Piette et al. [58] found that patient with higher
out-of-pocket costs were more likely to report cost-related non-
adherence when patients’ trust in their physician was low and
that low income was associated with cost-related nonadherence
only in the presence of low trust. In addition, it was found that
only few chronically ill patients share their economic difﬁculties
in purchasing medication with their clinician [59].
Patients’ ability to comprehend health information is vital to
maintaining and improving their health. It was estimated that
almost one third of the US population hold inadequate health
literacy [60]. Although physician practice may be affected by this
considerable public health problem, numerous studies have
found that physicians do not assess their patients’ health literacy
skills and address them efﬁciently [60]. Following the chronic
care model, health outcomes can be improved with patient
education and improved physician communication skills that
take into account patients’ health literacy levels [61–63]. This
patient-clinician partnership includes supporting patients to
improve their quality of life despite their chronic condition,
teaching problem-solving skills that are relevant to patients’ real
life, helping patients set goals, adjusting therapy to optimized
disease control, and ensuring follow-up rather than solely pro-
viding technical information [61–63]. Several recent studies share
an ongoing robust evidence that implementation of strategies
based on this concept improves chronically ill patients’ outcomes
[64–68]. Further research is warranted to explore whether poor
physician-patient communication that lead to cost-related non-
adherence stems from linguistic or cultural barriers. Our results,
however, highlight the need to incorporate measures to improve
the patient-clinician relationship in intervention strategies in
addition to applying an optimal co-payment design.
Our analysis is subject to several limitations. First, we sur-
veyed a representative sample of chronically ill patients, in one of
the four health plans in Israel. Hence, our results may not be
generalizable to the entire Israeli population because health
plans vary in their patients’ characteristics. Therefore, further
research among the three other health plans may be warranted.
Second, our analysis is based on a self-reported adherence and
not on objective measure. This may lead to inaccuracies relating
to patients’ memories and to the tendency of patients to provide
an answer that they think the interviewer views favorably [69].
This limitation, however, does not weaken our conclusions
because our study was not designed to measure the extent of
nonadherence but rather to explore its reasons. In addition,
although purchasing a medication does not ensure its use, a
recent study on the adherence and efﬁcacy of statins suggests
that a high association between medication purchase and actual
uptake exists [70]. Finally, our cross-sectional design provides a
snapshot to self-reported reasons of nonadherence that may be
time and consequence dependent. Further research that will
extract reasons for nonadherence in a longitudinal design of
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limitations, our study is, to our knowledge, the ﬁrst to evaluate
cost-related nonadherence among a representative cohort of
chronically ill patients in Israel. Our results suggest that this
ﬁnancial source of nonadherence is not marginal even in an
environment of universal health insurance coverage. Thus,
designing a beneﬁt structure that minimizes cost-related non-
adherence may improve adherence among up to 10% of patients.
The nature of these structures is still unclear because evidence of
the impact of VBIDs in decreasing cost-related nonadherence
from the United States is relatively ambiguous. Although one
analysis suggested that VBID decreased self-reported cost-related
nonadherence by 58% after the elimination of co-payment [28],
only modest reductions were found in others [30–32].Conclusions
We conclude that cost-related underuse of chronic pharmaceut-
ical therapy is self-reported among approximately 10% of the
chronically ill patients and is strongly affected by low socio-
economic status, as measured by lower income and unemploy-
ment, even under universal health insurance coverage and with
relatively low co-payments as applied in Israel. Moreover, lack of
information regarding the prescribed therapy provided by physi-
cians is associated with a higher likelihood of cost-related non-
adherence. Despite its recognized limitations, the ﬁndings from
our preliminary study support the removal of ﬁnancial barriers
for nonadherence in Israel. Because the current study analyzed
adherence to prescribed medication for chronically ill patients, it
seems that the risk of overutilization is less likely even if co-
payments will be reduced. In addition, the health insurance
coverage in Israel is provided by nonproﬁt organizations that
are ﬁnanced mainly through health and income tax payments
(not direct premiums). Thus, it is assumed that the potential
beneﬁt of VBID may outweigh its risks. Further research is
required for a longitudinal analysis of the pattern of health care
utilization of adherent and nonadherent chronically ill patients.
Evidence of both signiﬁcant rate of cost-related nonadherence
and negative association between adherence and long-term
health care expenditure may force health care policymakers to
adopt value-based insurance designs. These may include co-
payments differentiated by treatment value rather than by its
cost to improve adherence and outcomes with the potential of
reducing long-term health care spending.Acknowledgments
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